10 CFR §35.300
Verified against eCFR.gov as of June 20, 2026View official text on eCFR.gov ↗
A licensee may use any unsealed byproduct material identified in § 35.390(b)(1)(ii)(G) prepared for medical use and for which a written directive is required that is—
- (a)Obtained from:
- (b)Excluding production of PET radionuclides, prepared by:
- (1)An authorized nuclear pharmacist;
- (2)A physician who is an authorized user and who meets the requirements specified in §§ 35.290, 35.390, or
- (3)An individual under the supervision, as specified in § 35.27, of the authorized nuclear pharmacist in paragraph (b)(1) of this section or the physician who is an authorized user in paragraph (b)(2) of this section; or
- (c)Obtained from and prepared by an NRC or Agreement State licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA; or
- (d)Prepared by the licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA.